Mayukh Sukhatme Sells 17,519 Shares of Roivant Sciences (NASDAQ:ROIV) Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) insider Mayukh Sukhatme sold 17,519 shares of the firm’s stock in a transaction on Thursday, August 20th. The shares were sold at an average price of $37.30, for a total transaction of $653,458.70. Following the completion of the sale, the insider owned 18,630,739 shares in the company, valued at $694,926,564.70. The trade was a 0.09% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Mayukh Sukhatme also recently made the following trade(s):

• On Friday, August 21st, Mayukh Sukhatme sold 144,756 shares of Roivant Sciences stock. The stock was sold at an average price of $36.48, for a total transaction of $5,280,698.88.
• On Wednesday, August 19th, Mayukh Sukhatme sold 172,899 shares of Roivant Sciences stock. The stock was sold at an average price of $37.17, for a total transaction of $6,426,655.83.
• On Friday, August 14th, Mayukh Sukhatme sold 243,177 shares of Roivant Sciences stock. The shares were sold at an average price of $36.23, for a total value of $8,810,302.71.
• On Monday, August 17th, Mayukh Sukhatme sold 284,707 shares of Roivant Sciences stock. The shares were sold at an average price of $36.25, for a total value of $10,320,628.75.
• On Tuesday, August 18th, Mayukh Sukhatme sold 136,942 shares of Roivant Sciences stock. The stock was sold at an average price of $36.73, for a total value of $5,029,879.66.

Roivant Sciences Stock Performance

NASDAQ ROIV traded down $0.54 during trading on Friday, reaching $36.30. 6,185,493 shares of the company’s stock were exchanged, compared to its average volume of 5,631,176. The company has a 50 day moving average price of $34.61 and a two-hundred day moving average price of $30.43. The stock has a market cap of $26.22 billion, a P/E ratio of -68.49 and a beta of 1.12. Roivant Sciences Ltd. has a 1 year low of $11.60 and a 1 year high of $37.97.

Roivant Sciences (NASDAQ:ROIV) last released its quarterly earnings data on Friday, August 7th. The company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.04. Roivant Sciences had a negative return on equity of 22.94% and a negative net margin of 3,534.96%.The business had revenue of $1.44 million for the quarter, compared to the consensus estimate of $2.06 million. Research analysts forecast that Roivant Sciences Ltd. will post -2 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. Pictet Asset Management Holding SA raised its stake in shares of Roivant Sciences by 790.3% during the 4th quarter. Pictet Asset Management Holding SA now owns 2,312,436 shares of the company’s stock worth $50,180,000 after buying an additional 2,052,693 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Roivant Sciences by 8.4% in the 4th quarter. Vanguard Group Inc. now owns 42,059,041 shares of the company’s stock valued at $912,681,000 after buying an additional 3,254,113 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH boosted its stake in shares of Roivant Sciences by 90.9% in the fourth quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 80,561 shares of the company’s stock valued at $1,746,000 after buying an additional 38,354 shares in the last quarter. Nicholas Investment Partners LP boosted its stake in shares of Roivant Sciences by 13.9% in the fourth quarter. Nicholas Investment Partners LP now owns 279,856 shares of the company’s stock valued at $6,073,000 after buying an additional 34,235 shares in the last quarter. Finally, Jefferies Financial Group Inc. acquired a new position in Roivant Sciences during the fourth quarter worth $76,272,000. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on ROIV. Sanford C. Bernstein raised shares of Roivant Sciences to a “strong-buy” rating in a report on Wednesday, July 29th. TD Cowen restated a “buy” rating on shares of Roivant Sciences in a report on Thursday, August 6th. Guggenheim increased their target price on shares of Roivant Sciences from $36.00 to $42.00 and gave the company a “buy” rating in a research report on Friday, August 7th. HC Wainwright lifted their price target on shares of Roivant Sciences from $34.00 to $41.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Roivant Sciences in a research report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Roivant Sciences currently has an average rating of “Moderate Buy” and a consensus target price of $35.14.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.